Quarterly report · Q2
8129.TEDINET S100S94E
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥734.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥1.39T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥681.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥6.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥5.8bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.9bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥19.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥13.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥6.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥801.4bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥715.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥740.6bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥556.2bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥472.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥245.1bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥242.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥245.6bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥137.9bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥86.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥133.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥81.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥97.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥53.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥9m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥3.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥407m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥13.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥134.19 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥112.26 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥196.7 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥51.01 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.79 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥121.19 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.67 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.88 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 30.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥29.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥29.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥46.6bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥46.6bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥895m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥436m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥709.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥684.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥24.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥678m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥139m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥764.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥734.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥29.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥850m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥878m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥478m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥656.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥632.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥23.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥782m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥246m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥709.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥681.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥6.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 581
| Item | Context | Value | Unit |
|---|---|---|---|
| Impairment loss ope cf | Prior1YTDDuration | 26000000 | JPY |
| Impairment loss ope cf | CurrentYTDDuration | － | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 149000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 134000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | 27000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | 12000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | 121000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | 138000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | Prior1YTDDuration | -32000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | CurrentYTDDuration | -20000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | -98000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | 14000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -774000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -704000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 39000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 31000000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | Prior1YTDDuration | -35000000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | CurrentYTDDuration | 29000000 | JPY |
| Loss gain on sales and valuation of investment securities ope cf | Prior1YTDDuration | -7000000 | JPY |
| Loss gain on sales and valuation of investment securities ope cf | CurrentYTDDuration | -5127000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -24120000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | -36996000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -1891000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | 3237000000 | JPY |
| Decrease increase in other assets ope cf | Prior1YTDDuration | -3220000000 | JPY |
| Decrease increase in other assets ope cf | CurrentYTDDuration | -1073000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 36716000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 79022000000 | JPY |
| Increase decrease in other liabilities ope cf | Prior1YTDDuration | 2248000000 | JPY |
| Increase decrease in other liabilities ope cf | CurrentYTDDuration | 1901000000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | Prior1YTDDuration | -1384000000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | CurrentYTDDuration | 1552000000 | JPY |
| Other loss gain ope cf | Prior1YTDDuration | -854000000 | JPY |
| Other loss gain ope cf | CurrentYTDDuration | -728000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 15842000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 57553000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 777000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 700000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -36000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -31000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -6348000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -4765000000 | JPY |
| Other net ope cf subtotal | Prior1YTDDuration | 458000000 | JPY |
| Other net ope cf subtotal | CurrentYTDDuration | 477000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 10693000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 53933000000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -668000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -697000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 641000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 721000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |